Saturday 17 October 2026
Export IDYA’s income statement to Excel — free account
IDEAYA Biosciences, Inc.
IDYA Healthcare Biotechnology
IDEAYA Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $218.7 million, up 3,024.4% from fiscal 2024. In the quarter to June 2026, revenue grew 125.8%, EPS fell 38.6% and free cash flow fell 41.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
32.85
1.00
−2.95%
Follow IDYA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
10.79 | 13.26 | 12.90 | 14.65 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
16.94 | (33.80) | (39.32) | (38.90) | |
P/B ratio |
2.21 | 2.99 | 3.15 | 2.86 | |
Price to Tangible BV |
2.21 | 2.99 | 3.15 | 2.86 | |
EV/Sales |
7.26 | 10.49 | 9.97 | 11.11 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(15.86) | (34.03) | (26.58) | (23.30) | |
EV/FCF |
(15.39) | (32.93) | (25.98) | (22.85) | |
Quick Ratio |
12.20 | 10.87 | 10.35 | 10.03 | |
Current Ratio |
12.44 | 11.34 | 10.74 | 10.45 | |
Net Debt/EBITDA |
(7.32) | 6.74 | 6.18 | 6.78 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.18 | 0.21 | 0.22 | 0.20 | |
Operating CF/Net income |
1.19 | 1.09 | 0.76 | 0.78 | |
Capex/Depreciation |
0.04 | 1.02 | 14.22 | (8.41) | |
Research and Development Expense of Revenue |
39.93% | 796.24% | 1,459.24% | 1,227.15% | |
Selling, General and Administrative Expense of Revenue |
7.89% | 173.29% | 295.40% | 253.57% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
5.88% | 108.43% | 221.59% | 188.08% | |
Graham Net Nets |
0.29 | 0.19 | 0.20 | 0.22 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(6.76%) | (3.73%) | (4.74%) | (5.15%) | |
Free Cash Flow Yield |
(4.38%) | (2.40%) | (2.98%) | (3.32%) | |
Revenue per Share |
2.35 | 0.12 | 0.07 | 0.10 | |
Operating CF per Share |
1.61 | (1.02) | (0.85) | (0.96) | |
Capex per Share |
0.00 | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
1.61 | (1.03) | (0.86) | (0.97) | |
Cash per Share |
8.89 | 7.23 | 7.57 | 9.00 | |
Shareholders Equity per Share |
12.34 | 11.56 | 10.57 | 13.02 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.34 | 11.56 | 10.57 | 13.02 | |
Free Cash Flow |
142.17 | (90.83) | (76.14) | (89.08) | |
Working Capital |
738.15 | 607.91 | 631.28 | 781.35 | |
Capital Expenditures |
(0.04) | (0.33) | (0.97) | (0.87) | |
Net Current Asset Value |
709.55 | 580.34 | 603.03 | 753.23 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.03 | 0.15 | 0.10 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
15.50 | 16.50 | 19.18 | 23.89 | |
Average Assets |
1,212.50 | 1,116.71 | 1,065.49 | 1,175.48 | |
Average Common Equity |
1,136.23 | 1,041.04 | 980.70 | 1,079.28 |
Columns are period end dates